281 related articles for article (PubMed ID: 27184103)
21. Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers.
Brem J; van Berkel SS; Zollman D; Lee SY; Gileadi O; McHugh PJ; Walsh TR; McDonough MA; Schofield CJ
Antimicrob Agents Chemother; 2016 Jan; 60(1):142-50. PubMed ID: 26482303
[TBL] [Abstract][Full Text] [Related]
22. Drug Repurposing of the Unithiol: Inhibition of Metallo-β-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.
Grigorenko VG; Khrenova MG; Andreeva IP; Rubtsova MY; Lev AI; Novikova TS; Detusheva EV; Fursova NK; Dyatlov IA; Egorov AM
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163756
[TBL] [Abstract][Full Text] [Related]
23. Iminodiacetic Acid as a Novel Metal-Binding Pharmacophore for New Delhi Metallo-β-lactamase Inhibitor Development.
Chen AY; Thomas CA; Thomas PW; Yang K; Cheng Z; Fast W; Crowder MW; Cohen SM
ChemMedChem; 2020 Jul; 15(14):1272-1282. PubMed ID: 32315115
[TBL] [Abstract][Full Text] [Related]
24. Probing metallo-β-lactamases with molecular fragments identified by consensus docking.
Klingler FM; Moser D; Büttner D; Wichelhaus TA; Löhr F; Dötsch V; Proschak E
Bioorg Med Chem Lett; 2015 Nov; 25(22):5243-6. PubMed ID: 26463134
[TBL] [Abstract][Full Text] [Related]
25. Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
Lund BA; Christopeit T; Guttormsen Y; Bayer A; Leiros HK
J Med Chem; 2016 Jun; 59(11):5542-54. PubMed ID: 27165692
[TBL] [Abstract][Full Text] [Related]
26. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition.
Brem J; van Berkel SS; Aik W; Rydzik AM; Avison MB; Pettinati I; Umland KD; Kawamura A; Spencer J; Claridge TD; McDonough MA; Schofield CJ
Nat Chem; 2014 Dec; 6(12):1084-90. PubMed ID: 25411887
[TBL] [Abstract][Full Text] [Related]
27. New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition.
King DT; Worrall LJ; Gruninger R; Strynadka NC
J Am Chem Soc; 2012 Jul; 134(28):11362-5. PubMed ID: 22713171
[TBL] [Abstract][Full Text] [Related]
28. Structural Insights into TMB-1 and the Role of Residues 119 and 228 in Substrate and Inhibitor Binding.
Skagseth S; Christopeit T; Akhter S; Bayer A; Samuelsen Ø; Leiros HS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559248
[TBL] [Abstract][Full Text] [Related]
29. New Delhi metallo-β-lactamase I: substrate binding and catalytic mechanism.
Zheng M; Xu D
J Phys Chem B; 2013 Oct; 117(39):11596-607. PubMed ID: 24025144
[TBL] [Abstract][Full Text] [Related]
30. Structural and biochemical analysis of the metallo-β-lactamase L1 from emerging pathogen Stenotrophomonas maltophilia revealed the subtle but distinct di-metal scaffold for catalytic activity.
Kim Y; Maltseva N; Wilamowski M; Tesar C; Endres M; Joachimiak A
Protein Sci; 2020 Mar; 29(3):723-743. PubMed ID: 31846104
[TBL] [Abstract][Full Text] [Related]
31. Fluorinated captopril analogues inhibit metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose.
Kondratieva A; Palica K; Frøhlich C; Hovd RR; Leiros HS; Erdelyi M; Bayer A
Eur J Med Chem; 2024 Feb; 266():116140. PubMed ID: 38242072
[TBL] [Abstract][Full Text] [Related]
32. A fragment-based drug discovery strategy applied to the identification of NDM-1 β-lactamase inhibitors.
Caburet J; Boucherle B; Bourdillon S; Simoncelli G; Verdirosa F; Docquier JD; Moreau Y; Krimm I; Crouzy S; Peuchmaur M
Eur J Med Chem; 2022 Oct; 240():114599. PubMed ID: 35841882
[TBL] [Abstract][Full Text] [Related]
33. Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors.
Brindisi M; Brogi S; Giovani S; Gemma S; Lamponi S; De Luca F; Novellino E; Campiani G; Docquier JD; Butini S
J Enzyme Inhib Med Chem; 2016; 31(sup1):98-109. PubMed ID: 27121013
[TBL] [Abstract][Full Text] [Related]
34. Investigation of Dipicolinic Acid Isosteres for the Inhibition of Metallo-β-Lactamases.
Chen AY; Thomas PW; Cheng Z; Xu NY; Tierney DL; Crowder MW; Fast W; Cohen SM
ChemMedChem; 2019 Jul; 14(13):1271-1282. PubMed ID: 31124602
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and in vitro and biological evaluation of potent amino acid-derived thiol inhibitors of the metallo-β-lactamase IMP-1.
Arjomandi OK; Hussein WM; Vella P; Yusof Y; Sidjabat HE; Schenk G; McGeary RP
Eur J Med Chem; 2016 May; 114():318-27. PubMed ID: 27017264
[TBL] [Abstract][Full Text] [Related]
36. Recent research and development of NDM-1 inhibitors.
Wang T; Xu K; Zhao L; Tong R; Xiong L; Shi J
Eur J Med Chem; 2021 Nov; 223():113667. PubMed ID: 34225181
[TBL] [Abstract][Full Text] [Related]
37. Potential Inhibitors Against NDM-1 Type Metallo-β-Lactamases: An Overview.
Sharma S; Sharma S; Singh PP; Khan IA
Microb Drug Resist; 2020 Dec; 26(12):1568-1588. PubMed ID: 32486911
[TBL] [Abstract][Full Text] [Related]
38. 3-Bromopyruvate as a potent covalently reversible inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1).
Kang PW; Su JP; Sun LY; Gao H; Yang KW
Eur J Pharm Sci; 2020 Jan; 142():105161. PubMed ID: 31751778
[TBL] [Abstract][Full Text] [Related]
39. Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases.
Hu L; Yang H; Yu T; Chen F; Liu R; Xue S; Zhang S; Mao W; Ji C; Wang H; Xie H
Eur J Med Chem; 2022 Mar; 232():114174. PubMed ID: 35152091
[TBL] [Abstract][Full Text] [Related]
40. Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D).
Romero E; Oueslati S; Benchekroun M; D'Hollander ACA; Ventre S; Vijayakumar K; Minard C; Exilie C; Tlili L; Retailleau P; Zavala A; Elisée E; Selwa E; Nguyen LA; Pruvost A; Naas T; Iorga BI; Dodd RH; Cariou K
Eur J Med Chem; 2021 Jul; 219():113418. PubMed ID: 33862516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
